LSTA
Lisata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.65
+0.61%Aug 4, 2026, 11:00 UTC
Lisata Therapeutics filed a lawsuit against Kuva Labs Inc. and its subsidiary seeking damages for the benefit of its stockholders following the termination of a merger agreement.
Aug 4, 2026, 00:00 UTC
Lisata Therapeutics announced the termination of Dr. Kristen K. Buck as Executive Vice President of R&D and Chief Medical Officer, effective August 3, 2026, with severance benefits.
Aug 4, 2026, 00:00 UTC
Lisata Therapeutics granted James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer, a $200,000 gross cash retention bonus for continued employment through December 31, 2026.
Jul 17, 2026, 00:00 UTC
Lisata Therapeutics amended its merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp., extending the outside date from July 17, 2026 to July 21, 2026.
Jun 10, 2026, 12:00 UTC
Kuva Labs Inc. commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights.
Jun 9, 2026, 00:00 UTC
Lisata Therapeutics, Kuva Labs Inc., and Kuva Acquisition Corp. amended their merger agreement, extending the tender offer commencement deadline and the outside closing date.